AfghanistanTuberculosis profile
Population  2017 36 million
Estimates of TB burden*, 2017 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 10 (6–15) 29 (17–43)
Mortality (HIV+TB only) 0.064 (<0.01–0.17) 0.18 (0.03–0.47)
Incidence  (includes HIV+TB) 67 (43–96) 189 (122–270)
Incidence (HIV+TB only) 0.21 (0.14–0.3) 0.6 (0.39–0.86)
Incidence (MDR/RR-TB)** 3.2 (1.5–5.5) 9 (4.3–15)
Estimated TB incidence by age and sex (thousands)*, 2017
  0-14 years > 14 years Total
Females 3.5 (3.2–3.9) 31 (23–39) 34 (25–44)
Males 3.9 (3.5–4.3) 29 (22–36) 33 (24–42)
Total 7.4 (6.5–8.4) 60 (38–82) 67 (43–96)
TB case notifications, 2017  
Total cases notified 47 406
Total new and relapse 46 640
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 48%
          - % pulmonary 73%
          - % bacteriologically confirmed among pulmonary 61%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2017 70% (49–110)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2017 0.16 (0.08–0.26)
TB/HIV care in new and relapse TB patients, 2017 Number (%)
Patients with known HIV-status who are HIV-positive 7 <1%
          - on antiretroviral therapy 3 43%
Drug-resistant TB care, 2017 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  1 700
(1 000–2 300)
Estimated % of TB cases with MDR/RR-TB 3.7% (2–5.9) 21% (15–27)  
% notified tested for rifampicin resistance 6% 95% 5 251
MDR/RR-TB cases tested for resistance to second-line drugs   279
Laboratory-confirmed cases MDR/RR-TB: 279, XDR-TB: 5
Patients started on treatment **** MDR/RR-TB: 198, XDR-TB: 5
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2016 93% 40 287
Previously treated cases, excluding relapse, registered in 2016 90% 568
HIV-positive TB cases registered in 2016 0% 1
MDR/RR-TB cases started on second-line treatment in 2015 64% 83
XDR-TB cases started on second-line treatment in 2015   0
TB preventive treatment, 2017  
% of HIV-positive people (newly enrolled in care) on preventive treatment 4%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
> 100%
TB financing, 2018  
National TB budget (US$ millions) 11
Funding source: 5% domestic, 93% international, 2% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2017
age_sex_graph
____
 
FemalesMalesIncidence

Treatment success rate (%)
tx success graph
   New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__
Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2018-09-25 Data: www.who.int/tb/data